Abiopharma

🔍 Opipari Anthony W. (Executive)

Company: Odyssey Therapeutics, Inc. (ODTX)

Report Date: 2026-05-07

Detailed Transactions and Holdings:

• Acquired 6,965 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 6,965.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 541 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: M | equity_swap_involved: false | shares_owned_after: 7,506.00 | transaction_form_type: 4 | Footnotes: F5
• Sold 4 shares of Common Stock at $18.0 per share (Direct)
  Date: 2026-05-11 | Code: F | equity_swap_involved: false | shares_owned_after: 7,502.00 | transaction_form_type: 4 | Footnotes: F5, F6
• Sold 1,907 shares of Series A Convertible Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F7
• Sold 1,194 shares of Series B Convertible Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F2, F2, F2, F2, F7
• Sold 2,058 shares of Series C Convertible Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F3, F3, F3, F3, F7
• Sold 1,806 shares of Series D Convertible Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F4, F4, F4, F7
• Acquired 250,203 shares of Stock Option (Right to Buy) at $18.0 per share (Derivative)
  Date: 2026-05-07 | Code: A | Expires: 2036-05-06 | equity_swap_involved: false | shares_owned_after: 250,203.00 | transaction_form_type: 4 | Footnotes: F8
• Acquired 27,777 shares of Stock Option (Right to Buy) at $18.0 per share (Derivative)
  Date: 2026-05-07 | Code: A | Expires: 2036-05-06 | equity_swap_involved: false | shares_owned_after: 27,777.00 | transaction_form_type: 4 | Footnotes: F9
• Sold 541 shares of Series D Warrants (Right to Buy) at $0.1 per share (Derivative)
  Date: 2026-05-11 | Code: M | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F5, F5, F5

Footnotes:

• F1: The Series A Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
• F2: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration.
• F3: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
• F4: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
• F5: The warrants to purchase shares of common stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis.
• F6: Pursuant to the terms of the warrants, the Issuer withheld 4 warrant shares to pay the exercise price in connection with the net exercise.
• F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering.
• F8: Option vests in forty-eight (48) equal monthly installments, with the first installment scheduled to vest on June 7, 2026, subject to the Reporting Person's continued service on each such vesting date.
• F9: Option vests upon the first occurrence of the total market capitalization of the Issuer being equal to or in excess of $1,500,000,000, based on a 5-day volume-weighted average price of a share of Common Stock as traded on the Nasdaq Capital Market, subject to the Reporting Person's continued service on such vesting date.
• REMARKS: Interim Chief Medical Officer and Executive Vice President, Translational Medicine